Keryx Biopharmaceuticals, Inc. KERX is expected to report first-quarter 2017 results on May 4. Last quarter, the company missed expectations by 18.52%. In fact, Keryx’s performance over the last four quarters has been disappointing. The …
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of its short-term Phase 3 study of Zerenex (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or …
He tripled his position in KERX through purchases made in late February and early March. The stock was trading below $4 around that time. Currently KERX’s latest price is $4.59. Balyasny gained more than 15% in less than two months from …
I haven't exactly been a bull when it comes to Keryx Biopharmaceuticals (NASDAQ: KERX). For starters ... have provided all the warning I need to stay away from the stock. But things may be about to change. No, I'm still not interested in …
INGN closed Tuesday's trading at $101.65, up 0.50%. In after-hours, the stock was up 5.76% to $107.50. Keryx Biopharmaceuticals Inc.'s (KERX) supplemental new drug application of Auryxia for the treatment of patients with iron …
Keryx Biopharmaceuticals (NASDAQ:KERX - News) stock gained 5.94% to $2.14 +0.12 after the company announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 7th Annual JMP Securities Healthcare …
A year ago, they were trading at $5.41. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KERX at https://www.zacks.com/ap/KERX
Investors in Keryx Biopharmaceuticals, Inc. KERX need to pay close attention to the stock based on moves in the options market lately. That is because the January 19, 2018 $3 Put had some of the highest implied volatility of all equity …